Rwanda has taken a significant step toward strengthening its healthcare system through a new strategic partnership with Sandoz Group AG, a leading Swiss pharmaceutical company. The agreement is aimed at improving access to essential medicines, including life-saving cancer treatments, while tackling persistent challenges related to drug availability and affordability.
Signed in Kigali on April 15, 2026, the partnership reflects Rwanda’s broader commitment to expanding quality healthcare services and building a more resilient healthcare delivery system.
READ ALSO: World Health Day 2026: Celebrating Africa’s Health Triumphs, Confronting Tomorrow’s Challenges
The agreement was formalised by Rwanda’s Minister of Health, Sabin Nsanzimana, and Simon Goeller, Head of Strategy and Business Development at Sandoz. Under the arrangement, Sandoz will initially supply around 60 essential medicines, including antibiotics, generics, biosimilars, and cancer therapies, as part of its expanding footprint in African healthcare markets.
This marks an important milestone in Rwanda’s effort to improve public access to reliable and affordable medicines.
At the centre of the partnership is a direct supply model, designed to ensure a more stable flow of quality medicines while reducing the inefficiencies often associated with fragmented procurement systems.
In many African countries, medicine supply chains involve multiple intermediaries, increasing costs and delaying access to treatment. By streamlining procurement, Rwanda aims to lower costs, improve consistency in medicine delivery, and strengthen the efficiency of its public health infrastructure.
This approach could significantly improve treatment access for patients, particularly those managing chronic diseases and life-threatening conditions such as cancer.
For Sandoz, the partnership aligns with its global mission to expand healthcare access in underserved markets.
According to Simon Goeller, the agreement represents the beginning of a sustainable model for delivering affordable medicines to countries seeking stronger health outcomes. For Rwanda, the partnership is more than a procurement arrangement—it is a strategic alliance with one of the world’s most experienced producers of affordable medicines.
Headquartered in Basel, Switzerland, Sandoz is widely recognised for its expertise in generics and biosimilars, with a portfolio of approximately 1,300 products.
The company brings more than 140 years of pharmaceutical experience, including over 80 years in antibiotic manufacturing and 20 years in biosimilar development. With revenues of approximately $11.1 billion in 2025, Sandoz has the scale and operational capacity to support large-scale medicine access programmes.
This level of expertise gives Rwanda a reliable partner in addressing some of the most persistent gaps in medicine availability.
The timing of the partnership is especially important.
Rwanda has made substantial progress in healthcare reform over the past decade, expanding insurance coverage, improving public health systems, and strengthening treatment capacity for major diseases. It is among the few sub-Saharan African countries offering cancer treatment services, demonstrating a clear commitment to addressing both communicable and non-communicable diseases.
The partnership with Sandoz builds on this momentum.
By improving access to quality cancer therapies and essential medicines, Rwanda is enhancing its ability to respond to growing healthcare demands while improving outcomes for vulnerable populations.
Beyond immediate healthcare benefits, the agreement supports Rwanda’s longer-term ambition to become a regional hub for healthcare innovation and pharmaceutical access.
The country already hosts the headquarters of the African Medicines Agency, an institution established to harmonise medicine regulation across Africa and strengthen access to safe and effective treatments.
This new collaboration with Sandoz complements that vision.
It demonstrates how strategic partnerships with global pharmaceutical firms can support national health priorities while also contributing to broader continental efforts to improve medicine access.
The implications extend beyond Rwanda.
As healthcare demand rises across Africa, partnerships like this could help create more integrated pharmaceutical supply chains and improve access to essential medicines in neighbouring markets. Rwanda’s approach may provide a practical model for other African countries seeking to reform procurement systems, lower medicine costs, and improve public healthcare delivery.
This is particularly relevant at a time when global pharmaceutical companies are showing increasing interest in Africa’s healthcare market, recognising both the growing demand for medicines and the opportunity to support long-term health system development.
However, the long-term success of the agreement will depend on implementation.
Efficient logistics systems, effective regulatory coordination, and sustainable pricing structures will determine how quickly medicines reach the patients who need them. Without strong execution, even well-designed agreements may struggle to achieve their intended impact.
This means Rwanda must ensure that the operational systems supporting the partnership are as strong as the strategic vision behind it.
Despite these challenges, the partnership represents a major step forward.
It addresses one of the most persistent barriers to quality healthcare in Africa: the gap between medicine availability and patient access. By adopting a direct procurement approach and partnering with an experienced pharmaceutical provider, Rwanda is working to close that gap in a practical and scalable way.
Ultimately, Rwanda’s agreement with Sandoz reflects a forward-looking strategy for healthcare delivery.
By improving direct access to affordable, high-quality medicines and leveraging global expertise, the country is not only improving healthcare outcomes for its citizens but also creating a framework that other African nations can learn from.
As healthcare demands across the continent continue to grow, partnerships like this will become increasingly important.
They offer a path toward stronger health systems, better treatment access, and more sustainable healthcare delivery models.
Rwanda’s latest move shows that with the right partnerships, access to life-saving treatment can become not just an aspiration, but a practical reality.
